Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $7.4 million.

  • Praxis Precision Medicines' Share-based Compensation fell 4009.81% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year decrease of 1540.6%. This contributed to the annual value of $41.4 million for FY2024, which is 6639.18% up from last year.
  • Praxis Precision Medicines' Share-based Compensation amounted to $7.4 million in Q3 2025, which was down 4009.81% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Share-based Compensation ranged from a high of $14.5 million in Q1 2024 and a low of $5.7 million during Q4 2023
  • Over the past 4 years, Praxis Precision Medicines' median Share-based Compensation value was $7.6 million (recorded in 2023), while the average stood at $7.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 11572.1% in 2024, then crashed by 4009.81% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Share-based Compensation (Quarter) stood at $6.4 million in 2022, then fell by 10.05% to $5.7 million in 2023, then skyrocketed by 49.76% to $8.6 million in 2024, then decreased by 13.15% to $7.4 million in 2025.
  • Its Share-based Compensation stands at $7.4 million for Q3 2025, versus $7.8 million for Q2 2025 and $8.8 million for Q1 2025.